SB-509 / Biogen, Sangamo Therap - LARVOL DELTA

Sangamo BioSciences reports third quarter 2011 financial results (PRNewswire) - Sangamo's P2b Trial (SB-509-901) in subjects with moderately severe diabetic neuropathy did not meet key endpoints; Based on the data, the company announced that it has discontinued further development of SB-509

Discontinued • Pain

Sangamo BioSciences announces completion of enrollment of phase 2b clinical trial in diabetic neuropathy (PRNewswire) - Company expects to have efficacy data from this study in H1 ’11;

Anticipated launch • Pain

"It’s a great day for #Oklahoma patients! #SB509 has passed the Oklahoma House! Thank you @chad4ok @Conley4House @RepSheilaDills @MBlancett @CyndiMunson85 @MickeyDollens for supporting #steptherapy reform. On to the Governor’s desk! #oklege" (@NPF)

Clinical

"Thank you @tulsaworld for capturing the importance of #steptherapy reform and supporting #SB509 sponsored by Tulsa Sen. @CoachDaveRader & #HB2638 by Rep. @CyndiMunson85 @jonechols as commonsense protections for Oklahomans. https://t.co/aKLqX65WHG #NPFadvocacy #OKlege" (@NPF)